发明名称 Gene silencing by single-stranded polynucleotides
摘要 The present invention relates to compositions and methods for concurrently activating antisense and double-stranded RNase (dsRNase) mechanisms for inhibiting expression of a targeted gene, by delivering a single stranded bifunctional chimeric DNA/RNA oligonucleotide optimized for siRNA activity as well as antisense activity, into the nucleus of a target cell.
申请公布号 US9132148(B2) 申请公布日期 2015.09.15
申请号 US201313848249 申请日期 2013.03.21
申请人 GeneSegues, Inc. 发明人 Unger Gretchen M.
分类号 A61K31/7125;C12N15/11;C12N15/113 主分类号 A61K31/7125
代理机构 Swanson & Bratschun, L.L.C. 代理人 Swanson & Bratschun, L.L.C.
主权项 1. A method for inhibiting expression of a target gene in a tumor cell, wherein the target gene is Casein Kinase 2, comprising: administering a formulation of single stranded polynucleotides to a mammal in an amount sufficient to inhibit expression of the target gene in the tumor cell, wherein said formulation is prepared according to a process comprising: employing a suitable siRNA design algorithm to identify a candidate functional double stranded siRNA to a target RNA; synthesizing a single stranded polynucleotide sequence comprising at least a portion of the guidestrand of the candidate functional double stranded siRNA, wherein a functional single stranded polynucleotide consisting of 15-25 linked nucleosides without a self-complementary sequence region is formed; wherein the functional single stranded polynucleotide sequence comprises a 3′ RNA portion and a 5′ DNA portion, wherein the functional single stranded polynucleotide comprises at least three consecutive ribonucleotides at the 3′ end, wherein the functional single stranded polynucleotide is at least 50% DNA, wherein each of the internucleoside linkages of the functional single stranded polynucleotide is a phosphodiester linkage; and formulating a plurality of the functional single stranded polynucleotides, in the absence of a passenger strand, with a pharmaceutically acceptable non-viral carrier;wherein the formulation is introduced into the tumor cell,wherein the functional single stranded polynucleotides of the formulation are delivered to the perinuclear region or the nucleus of the tumor cell,whereupon said functional single-stranded polynucleotides concurrently activate dsRNAse and RNAseH mechanisms of the cell, thereby inhibiting expression of the target gene in the tumor cell.
地址 Chaska MN US